Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma
Qiyan Wang(Guiyang Medical University), Guizhi Zhu(University of Michigan), Katarzyna M. Tyc(Rutgers, The State University of New Jersey), Bo Wen(University of Michigan), Shimiao Liao(University of Michigan), Shurong Zhou(University of Michigan), Hanning Wen(University of Michigan), Chunpeng Yang(University of Michigan), Duxin Sun(University of Michigan), Ri Tang(Shanghai Jiao Tong University), Xiang Liu(Hangzhou Medical College), Mi Wang(Jiaxing University), Ting Su(Sun Yat-sen University), Furong Cheng(Cangzhou Central Hospital), You Xu(University of Michigan), Jinze Liu(Virginia Commonwealth University), Weijia Zheng(University of Victoria), Guolan Xiao(University of Michigan), Shaomeng Wang(University of Michigan), Jordan Dailey(University of Michigan)
Cited by 0
Related Papers
Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines
|Journal of Controlled Release|2022|344
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
|Cancer Research|2014|337
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
|Journal of Medicinal Chemistry|2018|261
Hyaluronic Acid-Decorated Graphene Oxide Nanohybrids as Nanocarriers for Targeted and pH-Responsive Anticancer Drug Delivery
|ACS Applied Materials & Interfaces|2014|202
A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation
|Nature Communications|2017|93